On July 31, Stryker declined 4.11% in regular trading, trading at $322.21/share, with turnover of $266 million.

The sell-off follows the company's Q2 earnings release on July 30 after market close. While adjusted EPS of $3.69 beat the consensus estimate of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, the MedSurg and Neurotechnology segment — its largest revenue contributor — reported $3.6 billion in sales, missing the $3.72 billion analyst expectation. Despite the strong Q2 EPS beat, the company only narrowed its full-year adjusted EPS guidance from $14.90-$15.10 to $14.95-$15.10, raising concerns over second-half growth sustainability. Additionally, lingering effects from a Q1 cybersecurity incident weighed on investor sentiment. Piper Sandler subsequently lowered its price target from $420 to $390, maintaining an Overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)